Investigation of resveratrol as a xanthine oxidase inhibitor: Mechanistic insights and therapeutic implications for gout and hyperuricemia

被引:0
|
作者
Chen, Jianmin [1 ,2 ,3 ]
Chen, Juan [1 ]
Feng, Baozhu [1 ]
Ning, Meilian [1 ]
Wu, Wanhui [1 ]
Zou, Shiqi [1 ]
机构
[1] Putian Univ, Sch Pharm, Putian 351100, Fujian, Peoples R China
[2] Putian Univ, Fujian Prov Univ, Key Lab Pharmaceut Anal, Putian, Fujian, Peoples R China
[3] Putian Univ, Fujian Prov Univ, Lab Med, Putian, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
allopurinol; hyperuricemia; resveratrol; uric acid; xanthine oxidase; URIC-ACID; IN-VITRO; OXIDOREDUCTASE; TOPIROXOSTAT; TYROSINASE;
D O I
10.1002/bab.2690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gout predominantly stems from hyperuricemia, precipitating the accumulation of urate crystals and consequent joint inflammation, swelling, and pain, thereby compromising the quality of life and presenting a formidable medical dilemma. Although conventional treatments like allopurinol and febuxostat target uric acid reduction via xanthine oxidase (XO) inhibition, they often entail adverse effects, prompting the exploration of safer alternatives. Resveratrol, a polyphenolic compound abundant in fruits and vegetables, has emerged as a potential XO inhibitor. However, its precise inhibitory mechanisms remain poorly understood. This study aims to comprehensively investigate resveratrol's XO inhibition through mechanistic insights, molecular docking simulations, animal model experiments, and biochemical analysis, contributing valuable insights to the development of novel therapeutics for hyperuricemia and gout.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Hiroshi Matsuo
    Eiji Ishikawa
    Hirofumi Machida
    Yasuhide Mizutani
    Akiko Tanoue
    Takahiro Ohnishi
    Tomohiro Murata
    Shinya Okamoto
    Toru Ogura
    Yuki Nishimura
    Hiroo Ito
    Masashi Yasutomi
    Kan Katayama
    Shinsuke Nomura
    Masaaki Ito
    Clinical and Experimental Nephrology, 2020, 24 : 307 - 313
  • [12] Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study
    Saito, Yuichi
    Tanaka, Atsushi
    Yoshida, Hisako
    Nakashima, Hitoshi
    Ban, Noriko
    Matsuhisa, Munehide
    Kobayashi, Yoshio
    Node, Koichi
    NUTRIENTS, 2024, 16 (14)
  • [13] Effects of acupuncture at Shu, Yuan, and Mu acupoints on blood serum uric acid and xanthine oxidase levels in a rat model of gout and hyperuricemia
    Wang Xinyi
    Liu Bingyun
    Wang Shan
    Sui Minghe
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2017, 37 (06) : 841 - 845
  • [14] Effects of acupuncture at Shu, Yuan, and Mu acupoints on blood serum uric acid and xanthine oxidase levels in a rat model of gout and hyperuricemia
    Wang Xinyi
    Liu Bingyun
    Wang Shan
    Sui Minghe
    JournalofTraditionalChineseMedicine, 2017, 37 (06) : 841 - 845
  • [15] Mechanistic insights into the inhibition of quercetin on xanthine oxidase
    Zhang, Cen
    Wang, Rui
    Zhang, Guowen
    Gong, Deming
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 112 : 405 - 412
  • [16] In Silico Prediction of Maize microRNA as a Xanthine Oxidase Inhibitor: A New Approach to Treating Hyperuricemia Patients
    Joshi, Manas
    Khan, Mohd Mabood
    NON-CODING RNA, 2025, 11 (01)
  • [17] Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes
    Guma, Monica
    Dadpey, Benyamin
    Coras, Roxana
    Mikuls, Ted R.
    Hamilton, Bartlett
    Quehenberger, Oswald
    Thorisdottir, Hilda
    Bittleman, David
    Lauro, Kimberly
    Reilly, Shannon M.
    Liu-Bryan, Ru
    Terkeltaub, Robert
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [18] The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinolstudy protocol
    Sakuma, Masashi
    Toyoda, Shigeru
    Arikawa, Takuo
    Koyabu, Yota
    Kato, Toru
    Adachi, Taichi
    Suwa, Hideaki
    Narita, Jun-ichi
    Anraku, Koetsu
    Ishimura, Kimihiko
    Yamauchi, Fumitake
    Sato, Yasunori
    Inoue, Teruo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (06) : 1379 - 1386
  • [19] Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout
    Yang, Xinye
    Li, Yong
    Pan, Shengqiang
    Ma, Facheng
    Chen, Hong
    Deng, Jinhui
    Yue, Jie
    Gong, Qijie
    Zheng, Mi
    Zeng, Ying
    Li, Jing
    Zhang, Yingjun
    Wang, Xiaojun
    Zhang, Xiaojin
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (16) : 14668 - 14691
  • [20] Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia
    Komoriya, K
    Hoshide, S
    Takeda, K
    Kobayashi, H
    Kubo, J
    Tsuchimoto, M
    Nakachi, T
    Yamanaka, H
    Kamatani, N
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) : 1119 - 1122